Abstract:
:Oral fingolimod (Gilenya™), a sphingosine 1-phosphate (S1P) receptor agonist, is the first oral agent and the first in a novel class of disease-modifying therapies (DMTs) to be approved for use in the US for the treatment of relapsing forms of multiple sclerosis (MS). In the EU, fingolimod is approved for use as a single-agent DMT in selected patients with highly-active, relapsing-remitting (RR) MS. This article reviews the pharmacological properties and clinical use of the drug in patients with RRMS. Fingolimod is rapidly converted in vivo to the active moiety S-fingolimod-phosphate, which binds with high affinity to S1P receptors, thereby sequestering lymphocytes in the lymph nodes and preventing their egress into the peripheral circulation. As a consequence, there is a reduction in the infiltration of autoaggressive lymphocytes into the CNS. Fingolimod-phosphate also acts as a functional antagonist, as its binding to S1P receptors results in their internalization and degradation, thereby downregulating S1P receptors on the lymphocyte cell surface. Since fingolimod crosses the blood : brain barrier, it also potentially acts at S1P receptors on neural cells in the CNS to mitigate neuropathological processes associated with MS. In large multinational trials in adult patients with RRMS, oral fingolimod 0.5 mg/day was more effective than oral placebo (FREEDOMS) and recommended dosages of intramuscular interferon-β (IFNβ)-1a (TRANSFORMS) in reducing the annualized relapse rate and was also generally more effective at slowing progression of neurological disability and at reducing the burden and activity of disease. Fingolimod was generally well tolerated in these trials of up to 2 years' duration, with most adverse events being manageable and of mild to moderate severity; there were two deaths from opportunistic infections, albeit these occurred with fingolimod 1.25 mg/day (higher than the recommended dosage). Limited long-term data indicated that no new safety concerns had arisen after 5 years of fingolimod treatment. However, further clinical experience is required to fully determine the long-term safety profile of fingolimod, particularly with regard to any potentially serious or life-threatening adverse events. In the absence of robust pharmacoeconomic studies and of head-to-head trials comparing fingolimod with other formulations of IFNβ and glatiramer acetate, the relative position of fingolimod with respect to other DMTs remains to be fully determined. In the meantime, given its convenient once-daily oral treatment regimen and better efficacy than intramuscular IFNβ-1a, fingolimod is a valuable emerging option for the treatment of adult patients with relapsing forms of MS.
journal_name
CNS Drugsjournal_title
CNS drugsauthors
Scott LJdoi
10.2165/11207350-000000000-00000subject
Has Abstractpub_date
2011-08-01 00:00:00pages
673-98issue
8eissn
1172-7047issn
1179-1934pii
4journal_volume
25pub_type
杂志文章,评审相关文献
CNS DRUGS文献大全abstract:BACKGROUND:There is growing epidemiological evidence that opioids may increase the risk of unintentional injuries and it is plausible that the time of initiation is most critical in that respect. Studies on fall-related injuries remain few, limited and mostly focused on specific groups of elderly patients. OBJECTIVE:T...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-013-0038-1
更新日期:2013-02-01 00:00:00
abstract::It is difficult to determine the relative efficacy of atypical antipsychotics for the treatment of schizophrenia, based on the available literature. The purpose of this article is to review and compare the efficacy of two atypical antipsychotics: olanzapine and ziprasidone.This review focused on randomised trials in w...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200519060-00003
更新日期:2005-01-01 00:00:00
abstract:INTRODUCTION:Cognitive impairment is prevalent and debilitating among persons with multiple sclerosis (MS). While many pharmacologic treatments have shown good efficacy in reducing clinical relapses, brain lesions, and improving certain physical symptoms, their efficacy for improving cognitive function is not well unde...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-020-00734-4
更新日期:2020-06-01 00:00:00
abstract::Clinically relevant movement disorders are identified in 3% of patients with HIV infection seen at tertiary referral centres. In the same setting, prospective follow-up shows that 50% of patients with AIDS develop tremor, parkinsonism or other extrapyramidal features. Hemiballism-hemichorea and tremor are the most com...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200216100-00002
更新日期:2002-01-01 00:00:00
abstract::In recent years, several new antiepileptic drugs (AEDs) have been licensed: felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide. These drugs have proven efficacy as add-on therapy in patients with difficult-to-treat partial epilepsy, as 20-50% of patients ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200317060-00003
更新日期:2003-01-01 00:00:00
abstract:BACKGROUND:Antidepressant-induced liver injury is a major concern and a liver monitoring scheme has been recommended by the European Medicines Agency for agomelatine. OBJECTIVE:The objective of this study was to assess the liver safety and identify the characteristics of patients who developed a significant increase i...
journal_title:CNS drugs
pub_type: 杂志文章,meta分析
doi:10.1007/s40263-016-0351-6
更新日期:2016-09-01 00:00:00
abstract:UNLABELLED:Tianeptine is an antidepressant agent with a novel neurochemical profile. It increases serotonin (5-hydroxytryptamine; 5-HT) uptake in the brain (in contrast with most antidepressant agents) and reduces stress-induced atrophy of neuronal dendrites. Like the selective serotonin reuptake inhibitors (SSRIs) and...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200115030-00006
更新日期:2001-01-01 00:00:00
abstract::Nucleoside analogue reverse transcriptase inhibitors (NRTIs), used as part of highly active antiretroviral therapy for the treatment of HIV and AIDS, disrupt neuronal mitochondrial DNA synthesis, resulting in antiretroviral toxic neuropathy (ATN). Acetyl-L-carnitine (ALC) enhances neurotrophic support of sensory neuro...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200721001-00004
更新日期:2007-01-01 00:00:00
abstract::Smokeless tobacco (SLT) is used in a variety of forms throughout the world. Long-term SLT use is associated with adverse health consequences. Effective pharmacotherapies are needed to treat SLT users who want to achieve tobacco abstinence. In the current review, we discuss the pharmacological interventions identified ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11598450-000000000-00000
更新日期:2012-01-01 00:00:00
abstract:BACKGROUND:There are few data about the cost effectiveness of prophylactic medications for migraine. Clinical trials have shown several preventive agents to be useful in reducing the frequency of migraine attack while having tolerable side effects. OBJECTIVE:To compare the cost effectiveness of adding preventive treat...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/11531180-000000000-00000
更新日期:2010-08-01 00:00:00
abstract:BACKGROUND:The molecules that provide access to activated T cells in the CNS, including chemokines, have been considered to be a crucial step in the pathogenesis of multiple sclerosis (MS). AIMS:In this study, we investigated serial serum chemokine levels in patients with relapsing-remitting MS over 1 year and the ass...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/11595060-000000000-00000
更新日期:2011-11-01 00:00:00
abstract::Given the high heritability of the disorder, attention-deficit hyperactivity disorder (ADHD) is common among parents of children with ADHD. Parental ADHD is associated with maladaptive parenting, negative parent-child interaction patterns and a diminished response to behavioural parent training. We describe our previo...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/11633910-000000000-00000
更新日期:2012-09-01 00:00:00
abstract::Loxapine is a well-established, first-generation antipsychotic agent. Loxapine inhalation powder (Adasuve(®)) was recently approved in the USA and the EU for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. Inhaled loxapine is delivered by a hand-held, single-dose, single-use...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-013-0075-9
更新日期:2013-06-01 00:00:00
abstract::Electroconvulsive therapy (ECT) is used in the treatment of severe psychiatric disorders. It involves the induction of a seizure for therapeutic purposes by the administration of a variable-frequency electrical stimulus via electrodes applied to the scalp. The original application of ECT in non-anaesthetised patients ...
journal_title:CNS drugs
pub_type: 指南,杂志文章,实务指引,评审
doi:10.2165/00023210-200519090-00002
更新日期:2005-01-01 00:00:00
abstract::Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial-onset seizu...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11208340-000000000-00000
更新日期:2011-10-01 00:00:00
abstract:BACKGROUND:Cenobamate is a novel tetrazole-derived carbamate compound with a dual mechanism of action. This drug can enhance the inactivated state of voltage-gated sodium channels, preferentially inhibiting the persistent component of the sodium channel current, and acts as a positive allosteric modulator of GABAA rece...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-020-00759-9
更新日期:2020-11-01 00:00:00
abstract::Postherpetic neuralgia, which occurs most typically in older persons, is one of the most common and serious complications of herpes zoster (or shingles). It is a chronic neuropathic pain syndrome and remains one of the most difficult pain disorders to treat. Known beneficial agents include antidepressants, antiepilept...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200317110-00001
更新日期:2003-01-01 00:00:00
abstract::Dravet syndrome (DS) is a medically refractory epilepsy that onsets in the first year of life with prolonged seizures, often triggered by fever. Over time, patients develop other seizure types (myoclonic, atypical absences, drops), intellectual disability, crouch gait and other co-morbidities (sleep problems, autonomi...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-018-0511-y
更新日期:2018-04-01 00:00:00
abstract::The pervasive and devastating nature of substance use disorders underlies the need for the continued development of novel pharmacotherapies. We now know that glia play a much greater role in neuronal processes than once believed. The various types of glial cells (e.g., astrocytes, microglial, oligodendrocytes) partic...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-020-00721-9
更新日期:2020-07-01 00:00:00
abstract:BACKGROUND:Statins possess neuroprotective effects. However, real-world evidence supporting their utility in post-stroke epilepsy (PSE) prevention is limited. OBJECTIVE:The association between statin use, including timing of prescribing (pre-stroke vs post-stroke), type (lipophilicity, intensity of therapy) and dose i...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-018-0501-0
更新日期:2018-04-01 00:00:00
abstract::Once considered rare and resistant to treatment, obsessive-compulsive disorder (OCD) has now emerged as a common, yet often unrecognized, psychiatric condition. Treatment with selective serotonin reuptake inhibitors (SSRIs) is effective in 40-60% of patients with OCD. Management of the remaining 40-60% of patients wit...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11587860-000000000-00000
更新日期:2011-07-01 00:00:00
abstract::Ursolic acid is a pentacyclic triterpenoid found in several plants. Despite its initial use as a pharmacologically inactive emulsifier in pharmaceutical, cosmetic and food industries, several biological activities have been reported for this compound so far, including anti-tumoural, anti-diabetic, cardioprotective and...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-017-0474-4
更新日期:2017-12-01 00:00:00
abstract:BACKGROUND:Several small studies have shown beneficial effects of ondansetron, a serotonin 5-HT(3) receptor antagonist, in the treatment of obsessive-compulsive disorder (OCD). The efficacy of other 5-HT(3) receptor antagonists in patients with OCD is still unclear. Granisetron does not alter cytochrome P450 activity a...
journal_title:CNS drugs
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.2165/11635850-000000000-00000
更新日期:2012-10-01 00:00:00
abstract::Statins, or 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, such as lovastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, rosuvastatin and pitavastatin, are cholesterol-lowering drugs used in clinical practice to prevent coronary heart disease. These drugs are generally well tolerated and have ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-013-0135-1
更新日期:2014-03-01 00:00:00
abstract::Premature mortality due to cardiovascular disease in those with schizophrenia is the largest lifespan disparity in the US and is growing; adults in the US with schizophrenia die, on average, 28 years earlier than those in the general population. The rate of smoking prevalence among individuals with schizophrenia is es...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-017-0438-8
更新日期:2017-06-01 00:00:00
abstract:BACKGROUND:Few studies examine predictors of seizures in medically treated patients with epilepsy receiving antiepileptic monotherapy using a large patient population. OBJECTIVE:Our objective was to identify clinical, medication, and demographic factors associated with seizure recurrence in medically treated patients ...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-014-0191-1
更新日期:2014-11-01 00:00:00
abstract::The issue of antipsychotic treatment during pregnancy is subject to substantial uncertainty and some controversy among healthcare providers, specifically pertaining to second-generation antipsychotics (SGAs) that are subject to a large gap in safety data during pregnancy compared with antidepressants. The amount of sa...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-018-0517-5
更新日期:2018-04-01 00:00:00
abstract::Parkinson's disease is a disabling hypokinetic neurological movement disorder in which the aetiology is unknown in the majority of cases. Current pharmacological treatments, though effective at restoring movement, are only symptomatic and do nothing to slow disease progression. Electrophysiological, epidemiological an...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-016-0393-9
更新日期:2016-12-01 00:00:00
abstract::Numerous in vitro and in vivo experimental animal studies have demonstrated that gangliosides, particularly GMI ganglioside (siagoside), may stimulate or accelerate the repair of peripheral and central nervous system neurons after various types of damage. Clinical studies of GMl in peripheral neuropathies and stroke, ...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/00023210-199401030-00006
更新日期:1994-03-01 00:00:00
abstract::Despite several decades of research, the characteristics distinguishing atypical depression from other depressive subtypes remain ambiguous. Multiple lines of evidence support the designation of atypical depression as a scientifically and clinically relevant subtype, including differences in hormonal responses, brain ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11310990-000000000-00000
更新日期:2009-12-01 00:00:00